F. Xavier Bosch mainly focuses on Cervical cancer, Internal medicine, Gynecology, HPV infection and Oncology. He studies HPV vaccines, a branch of Cervical cancer. In most of his Internal medicine studies, his work intersects topics such as Immunology.
F. Xavier Bosch has researched Gynecology in several fields, including Dermatology, Cervix and Obstetrics. F. Xavier Bosch focuses mostly in the field of HPV infection, narrowing it down to matters related to Disease and, in some cases, Health care, Anal cancer and Family medicine. His research in Oncology intersects with topics in Cancer, Human Papillomavirus DNA Test, Epidemiology, Linear Array HPV Genotyping Test and Larynx.
F. Xavier Bosch mostly deals with Cervical cancer, Gynecology, Internal medicine, Cancer and Oncology. His study in Cervical cancer is interdisciplinary in nature, drawing from both Human papillomavirus, Epidemiology and Vaccination. His Gynecology research includes themes of Odds ratio, Cervix, Papillomaviridae, Obstetrics and Cervical intraepithelial neoplasia.
The concepts of his Internal medicine study are interwoven with issues in Immunology and Vaccine efficacy. His study explores the link between Cancer and topics such as Risk factor that cross with problems in Case-control study, Carcinoma in situ and Logistic regression. His work carried out in the field of Oncology brings together such families of science as Adenocarcinoma, Attributable risk and Pathology.
His scientific interests lie mostly in Cervical cancer, Gynecology, Vaccination, Internal medicine and Human papillomavirus. Cervical cancer is a subfield of Cancer that he studies. His studies deal with areas such as Cytology and Obstetrics as well as Gynecology.
His Vaccination research incorporates themes from Clinical trial, Environmental health, Young adult, Hpv vaccination and Cervical intraepithelial neoplasia. The study incorporates disciplines such as Genotyping and Oncology in addition to Internal medicine. His Oncology research incorporates elements of Carcinoma and Pathology.
The scientist’s investigation covers issues in Internal medicine, Vaccination, Cervical intraepithelial neoplasia, Oncology and Cervical cancer. All of his Internal medicine and Cohort and Risk factor investigations are sub-components of the entire Internal medicine study. His Vaccination research is multidisciplinary, relying on both Young adult and Clinical trial.
The Cervical intraepithelial neoplasia study which covers HPV infection that intersects with Immunology, Vaccine efficacy and Randomized controlled trial. His biological study spans a wide range of topics, including Cancer, HPV vaccines and Pathology. His studies in Cervical cancer integrate themes in fields like Medical record, Gynecology, Time trends and Human papillomavirus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
Nubia Muñoz;F. Xavier Bosch;Silvia de Sanjosé;Rolando Herrero.
The New England Journal of Medicine (2003)
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
F. Xavier Bosch;M. Michele Manos;Nubia Muñoz;Mark Sherman.
Journal of the National Cancer Institute (1995)
Primary liver cancer: Worldwide incidence and trends
F.Xavier Bosch;Josepa Ribes;Mireia Díaz;Ramon Cléries.
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa;Gonzalo Perez;Susanne K. Kjaer;Jorma Paavonen.
The New England Journal of Medicine (2007)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose;Wim G.V. Quint;Laia Alemany;Daan T. Geraets.
Lancet Oncology (2010)
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.
Silvia de Sanjosé;Mireia Diaz;Xavier Castellsagué;Gary Clifford.
Lancet Infectious Diseases (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen;David Jenkins;F. Xavier Bosch;Paulo Naud.
The Lancet (2007)
Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
Nubia Muñoz;F. Xavier Bosch;Xavier Castellsagué;Mireia Díaz.
International Journal of Cancer (2004)
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.
Rolando Herrero;Xavier Castellsagué;Michael Pawlita;Jolanta Lissowska.
Journal of the National Cancer Institute (2003)
Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings
Laia Bruni;Mireia Diaz;Mireia Castellsagué;Elena Ferrer.
The Journal of Infectious Diseases (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: